A few days ago, Shenzhen Small and medium-sized Enterprise Service Bureau released the "Shenzhen Small and Medium-sized Enterprise Service Bureau- the list of Shenzhen SRDI small and medium-sized enterprises in 2022", after enterprise declaration, expert review and other aspects, with the outstanding performance of children medicine field, Shenzhen Beimei Pharmaceutical Co., Ltd. was identified as a "Shenzhen SRDI enterprise”!

SRDI (Specialized-Refinement--Differential-Innovation)

SRDI stands for specialization, refinement, differentiation and innovation, in line with the above characteristics, the enterprise is called “SRDI enterprise.” The main business and development focus of the enterprise are required to meet the national industrial policies and related requirements, such as characteristics of specialization, refinement, differentiation and innovation. Also, the characteristics of having strong innovation ability, high-speed development; and at the leading level of the market, quality, efficiency and development are also required, which bring the enterprises become advanced and exemplary.

This is another authoritative recognition of Shenzhen Beimei Pharmaceutical Co., Ltd. after the national high-tech enterprise identification and the 11th "China Innovation and Entrepreneurship Competition Excellent Enterprise", which will become another milestone in the development of Beimei Pharmaceutical.

In the future, Beimei Pharmaceutical will take the qualification of "Shenzhen SRDI enterprise" as the new starting point, and continue to contribute to the development of Chinese children's pharmaceutical field with specialization, refinement, differentiation and innovation as the standard.

About Shenzhen Beimei Pharmaceutical Co., Ltd.

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated. 

For more information, please visit our website at http://www.beimeiyaoye.com